BiomX Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
HLSQ$0.11-13.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Research and development (“R&D”) expenses, net | 21,292 | 24,663 |
| General and administrative expenses | 9,628 | 11,776 |
| Gain from early lease termination | (2,949) | - |
| Goodwill impairment | - | 801 |
| IPR&D impairment | 11,842 | 3,237 |
| Other long-lived assets impairment | 1,653 | 4,046 |
| Operating loss | 41,466 | 44,523 |
| Other expense (income) | 93 | (2,143) |
| Interest expenses | 20 | 873 |
| Finance expense , net | 724 | 919 |
| Income from change in fair value of warrants | (6,111) | (26,458) |
| Loss before tax | 36,192 | 17,714 |
| Tax expenses | 7 | 13 |
| Net Loss | 36,199 | 17,727 |
| Basic loss per share of Common Stock | 22.19 | 25.37 |
| Diluted loss per share of Common Stock | 22.19 | 58.31 |
| Weighted average number of shares used in computing basic loss per share of Common Stock (*) | 1,631,037 | 698,870 |
| Weighted average number of shares used in computing diluted loss per share of Common Stock (*) | 1,631,037 | 757,749 |
| (*) | All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 12A. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.